AI-powered PET scans may predict prostate cancer aggressiveness before surgery
NCT ID NCT07655648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a special type of PET scan, using two different tracers, can help predict how aggressive a person's prostate cancer is before surgery. Researchers will use computer models to analyze the scan images and compare the results with standard biopsy and surgical findings. The goal is to see if this imaging method can better classify cancer risk and predict whether the cancer might come back after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gallium-68 labeled PSMA and RM26
What this could lead to
If successful, this approach could help doctors determine prostate cancer aggressiveness without invasive biopsy, guiding treatment decisions more accurately.
What could go wrong
This is a small, retrospective study at a single center. The model may not work as well in other hospitals or diverse patient groups, and it is not yet ready for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Nuclear Medicine, Xiangya Hospital, Central South University
Changsha, Hunan, China